MONTREAL, July 24 /CNW Telbec/ - Akela Pharma Inc. (TSX: “AKL”), a drug development company focused on developing therapies for the inhalation and pain markets, today announced that it has been awarded a contract at its PharmaForm subsidiary located in Austin, Texas, to process validate and manufacture Phase III Registration Batches for Proellex(R), a drug product developed by Repros Therapeutics, Inc (NASDAQ: “RPRX”).
